Research is at the heart of advances in treatment and care for Duchenne muscular dystrophy and funding Duchenne research is a core objective for Parent Project Muscular Dystrophy (PPMD). PPMD’s research programs, which run the gamut from small bridge grants to seven figure awards for drug development, are all designed to fund projects directly aimed at the development of new therapies for Duchenne.
Applications to PPMD are reviewed by either:
PPMD uses an online grant submission and management system to reduce the burden of paper and to standardize our procedures. View our available funding opportunities below, and then click the “Apply for Funding” button.
Current Funding Opportunities
- REQUEST FOR APPLICATIONS – Xcelerate Duchenne Drug Development
As part of its Xcelerate program PPMD is soliciting drug development projects for Duchenne muscular dystrophy that are in the late preclinical or early clinical stages. Funding range is from $500,000 - $1,000,000 per project over two years. View the RFA.
Deadlines and Dates
RFA Released: March 5, 2014
Applications Due: April 1, 2014
Reviews Due: May 16, 2014
Review Responses Due: June 13, 2014
Review Meeting: June 27, 2014
Funding Start: July 15, 2014
- Exploratory Awards
The next deadline for submitting Exploratory Awards will be August 15th, details forthcoming. PPMD has developed the PPMD Exploratory Award for the development of preliminary data for new ideas or studies that are highly relevant to Duchenne muscular dystrophy therapy development. View the Exploratory Funds page for more information.
Rapid and open sharing of new research data, analyses, and ideas. PLoS Currents: Muscular Dystrophy enables research results and ideas to be shared immediately while ensuring that they will be permanently archived and citable. PLoS Currents provides open access to all content, ensuring that authors reach the widest possible audience. All content is reviewed by a group of expert researchers. PPMD is proud to provide support to launch and maintain PLoS Currents: Muscular Dystrophy.
In this section
Apply for Funding
Xcelerate Duchenne Drug Development